Dr. Garon on Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD
Published: Thursday, Aug 31, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 
SELECTED
LANGUAGE


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses antiangiogenic agents in patients with lung cancer.

Enthusiasm for antiangiogenic agents has waned although the data have not changed, states Garon. There is a benefit in overall survival, progression-free survival, and an objective response rate when antiangiogenic therapies are added in combination with other agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x